Allspring Global Investments Holdings LLC Acquires 13,111 Shares of DexCom, Inc. (NASDAQ:DXCM)

Allspring Global Investments Holdings LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 28.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 58,571 shares of the medical device company’s stock after acquiring an additional 13,111 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in DexCom were worth $4,596,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc bought a new stake in shares of DexCom in the 4th quarter valued at about $25,000. Heck Capital Advisors LLC bought a new position in shares of DexCom in the fourth quarter valued at $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom during the 3rd quarter valued at about $57,000. Covestor Ltd grew its holdings in DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after buying an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its stake in shares of DexCom by 46.7% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after acquiring an additional 265 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Citigroup lifted their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

Insider Activity

In related news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

DXCM opened at $89.34 on Friday. The firm has a market capitalization of $34.90 billion, a PE ratio of 62.48, a price-to-earnings-growth ratio of 2.33 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business’s 50-day moving average is $83.06 and its two-hundred day moving average is $75.85. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts anticipate that DexCom, Inc. will post 2.02 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.